Could this Healthcare Stock really climb 417.24% in 2024?

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Revolutionary Device Redefines Cancer Detection]( [Learn More Now - Before Anticipated FDA Approval in 2024]( --------------------------------------------------------------- February 29, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Detecting Cancer in 1.5 Seconds: Early Investment Opportunity]( Stanford engineer's lofty goal of revolutionizing cancer diagnostics is expected to come to fruition with FDA review in its final stages. With a history of taking companies public, including a $2 billion market cap NASDAQ company, this may be his biggest venture yet! With the ability to detect cancer's "molecular fingerprint" in just 1.5 seconds, it also offers far superior accuracy to current detection methods! [Learn more about how this could transform the multi-billion dollar diagnostic market.]( --------------------------------------------------------------- [Tidewater Inc.]( Symbol: [TDW]( Recent Price: $70.37 Average Analyst Price Target: $88.25 (25.41%) Market Cap: $3.72B Last Year's EPS: $0.43 Consensus EPS Forecast: $1.45 Expected Earnings Date: Mar 01, 2024 Recent Analyst Action: Don Crist, analyst at Johnson Rice, reiterates coverage on [Tidewater Inc. (TDW)]( in the Energy sector with a Buy rating and a price target of $88 (2 weeks ago). [TipRanks.com]( also reports that [Tidewater Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $88.25 . The target pricing ranges from a high forecast of $90 down to a low forecast of $85. [Tidewater Inc. (TDW)](’s last closing price was $70.37 which would put the average price target at 25.41% upside. Here are 3rd party ratings for [TDW](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Bottom 9% (228 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [URGENT: Don't risk your retirement]( looming recession, inflation, unpayable debt, a failing dollar, and a crumbling housing market all put your savings in extreme risk. Protect your retirement with this free guide that shows you how to guard your money against economic downturns with gold. Take action NOW, before it’s too late, Download your free guide and see for yourself why gold is the #1 safe haven for smart investors. [Protect your retirement with this free gold guide]( --------------------------------------------------------------- [Biodesix, Inc.]( Symbol: [BDSX]( Recent Price: $1.53 Average Analyst Price Target: $3.50 (128.76%) Market Cap: $137.98M Last Year's EPS: $-0.17 Consensus EPS Forecast: $-0.15 Expected Earnings Date: Mar 01, 2024 Recent Analyst Action: Kyle Mikson, analyst at Canaccord Genuity, reiterates coverage on [Biodesix, Inc. (BDSX)]( in the Healthcare sector with a Buy rating and a price target of $3.5 (2 months ago). [TipRanks.com]( also reports that [Biodesix, Inc.]( currently has 1 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $3.50 . The target pricing ranges from a high forecast of $3.5 down to a low forecast of $3.5. [Biodesix, Inc. (BDSX)](’s last closing price was $1.53 which would put the average price target at 128.76% upside. Here are 3rd party ratings for [BDSX](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 32% (80 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Rare Chance to Be an Early Investor in AI Energy Breakthrough]( expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors. [Just go here for full details.]( --------------------------------------------------------------- [inTEST Corporation]( Symbol: [INTT]( Recent Price: $11.53 Average Analyst Price Target: $22.67 (96.59%) Market Cap: $140.22M Last Year's EPS: $0.28 Consensus EPS Forecast: $0.25 Expected Earnings Date: Mar 01, 2024 Recent Analyst Action: Jaeson Schmidt, analyst at Lake Street, reiterates coverage on [inTEST Corporation (INTT)]( in the Technology sector with a Buy rating and a price target of $19 (2 days ago). [TipRanks.com]( also reports that [inTEST Corporation]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $22.67 . The target pricing ranges from a high forecast of $29 down to a low forecast of $19. [inTEST Corporation (INTT)](’s last closing price was $11.53 which would put the average price target at 96.59% upside. Here are 3rd party ratings for [INTT](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 28% (179 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Compass Therapeutics, Inc.]( Symbol: [CMPX]( Recent Price: $1.74 Average Analyst Price Target: $9.00 (417.24%) Market Cap: $221.83M Last Year's EPS: $-0.09 Consensus EPS Forecast: $-0.11 Expected Earnings Date: Mar 01, 2024 Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on [Compass Therapeutics, Inc. (CMPX)]( in the Healthcare sector with a Buy rating and a price target of $10 (1 month ago). [TipRanks.com]( also reports that [Compass Therapeutics, Inc.]( currently has 2 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $9.00 . The target pricing ranges from a high forecast of $8 down to a low forecast of $10. [Compass Therapeutics, Inc. (CMPX)](’s last closing price was $1.74 which would put the average price target at 417.24% upside. Here are 3rd party ratings for [CMPX](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Buy, Top 34% (85 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Musk: My new robots could be bigger than Tesla]( No one can deny Elon Musk is a visionary. But has he finally gone too far? [>>See the shocking future of AI here<<]( --------------------------------------------------------------- [Ur-Energy Inc.]( Symbol: [URG]( Recent Price: $1.57 Average Analyst Price Target: $2.74 (74.36%) Market Cap: $417.60M Last Year's EPS: $-0.03 Consensus EPS Forecast: $-0.00438 Expected Earnings Date: Mar 01, 2024 Recent Analyst Action: Matt Key, analyst at B.Riley Financial, reiterates coverage on [Ur-Energy Inc. (URG)]( in the Energy sector with a Buy rating and a price target of $3 (3 weeks ago). [TipRanks.com]( also reports that [Ur-Energy Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $2.74 . The target pricing ranges from a high forecast of $3 down to a low forecast of $2.5. [Ur-Energy Inc. (URG)](’s last closing price was $1.57 which would put the average price target at 74.36% upside. Here are 3rd party ratings for [URG](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: buy - Zacks.com: Buy, Bottom 41% (147 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Game-Changing Cancer Tech Nears FDA Completion]( the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it. [Explore Investment Opportunities in This Market Disruptor]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketMoverAlerts.com Disclaimer This email/newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this email/newsletter is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this email/newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our email/newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.[If you are not a human, click here.](By opening and/or clicking on any link contained within this email, you are reconfirming your opt-in status. You can unsubsubscribe at any time by clicking on the link in the footer. MarketMoverAlerts.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software